Table 1.
Males: Statistically significant urinary metabolites identified by VIAVC or MW testing in the comparison of high and low maternal composite subjective distress and objective hardship in males. Significance was determined using a p-value equal to or less than 0.05. Metabolites are displayed in order of VIAVC p-value. Regulation relates to the high-strM Metabolites with more than one NMR resonance peak are represented in order of ppm as metabolite.1, metabolite.2, etc.
| Group | Metabolite | NMR Chemical Shift Range of Bin (ppm) | VIAVC | Mann-Whitney U Test | Regulation |
|---|---|---|---|---|---|
| Male Subjective Distress (COSMOSS) |
3-Hydroxyisovalerate | 1.281–1.27 | 5.98 × 10−122 | Not sig. | Up |
| Indole-3-lactate.1 | 7.285–7.263 | 3.56 × 10−82 | Not sig. | Up | |
| Creatine.1 | 3.947–3.929 | 1.32 × 10−65 | 1.04 × 10−2 | Down | |
| Glycylproline | 3.929–3.916 | 3.92 × 10−53 | Not sig. | Down | |
| Methylguanidine | 2.875–2.86 | 6.83 × 10−48 | Not sig. | Down | |
| Citramalic acid | 2.75–2.733 | 5.51 × 10−37 | Not sig. | Down | |
| Creatine.2 | 3.045–3.03 | 2.19 × 10−36 | 2.57 × 10−2 | Down | |
| Carnosine | 2.671–2.662 | 3.09 × 10−30 | Not sig. | Up | |
| Carnitine | 3.227–3.215 | 1.20 × 10−29 | Not sig. | Down | |
| 3-Chlorotyrosine | 7.129–7.116 | 3.25 × 10−27 | Not sig. | Down | |
| 3-Methylhistamine | 3.723–3.712 | 1.40 × 10−23 | 2.17 × 10−3 | Up | |
| Indole-3-lactate.2 | 4.383–4.33 | 2.10 × 10−23 | 2.04 × 10−3 | Up | |
| (S)-3-Hydroxyisobutyric acid | 1.116–1.105 | 2.98 × 10−23 | Not sig. | Down | |
| O-Phosphocholine | 3.241–3.227 | 4.17 × 10−19 | 4.45 × 10−4 | Down | |
| Male Objective Hardship (QFOSS) | Xanthurenate | 7.105–7.095 | 1.41 × 10−83 | Not sig. | Up |
| Cysteine | 3.011–2.996 | 2.01 × 10−65 | Not sig. | Down | |
| 3-Aminoisobutyrate.1 | 3.118–3.101 | 3.02 × 10−48 | Not sig. | Down | |
| Creatine.1 | 3.947–3.929 | 5.98 × 10−47 | Not sig. | Down | |
| Creatinine.1 | 3.066–3.045 | 1.06 × 10−41 | Not sig. | Down | |
| Erythritol, Glycylproline | 3.643–3.604 | 1.78 × 10−35 | Not sig. | Up | |
| Gluconate.1 | 4.053–4.03 | 5.96 × 10−34 | 8.03 × 10−3 | Up | |
| Dimethyl sulfone | 3.164–3.156 | 2.37 × 10−33 | Not sig. | Up | |
| Acetate | 1.932–1.919 | 3.58 × 10−30 | Not sig. | Up | |
| Creatine.2 | 3.045–3.03 | 5.73 × 10−28 | Not sig. | Down | |
| 5-Hydroxylysine.1 | 1.963–1.953 | 1.11 × 10−24 | Not sig. | Up | |
| Creatinine.2 | 4.081–4.053 | 9.63 × 10−24 | Not sig. | Down | |
| 2-Methylbutyroylcarnitine.1 | 0.8867–0.8768 | 5.24 × 10−23 | Not sig. | Down | |
| 5-Hydroxylysine.2, Glutathione | 2.963–2.942 | 3.40 × 10−22 | Not sig. | Up | |
| Carnosine.1 | 2.702–2.684 | 2.02 × 10−19 | Not sig. | Up | |
| 5-Hydroxylysine.3 | 3.172–3.164 | 7.56 × 10−19 | Not sig. | Up | |
| 3-Aminoisobutyrate.2 | 1.196–1.185 | 1.49 × 10−18 | Not sig. | Up | |
| 4-Pyridoxic acid | 2.358–2.339 | 7.62 × 10−17 | Not sig. | Up | |
| Vanylglycol | 3.375–3.366 | 1.19 × 10−15 | Not sig. | Up | |
| Gluconate.2 | 4.157–4.134 | 1.66 × 10−15 | 4.05 × 10−2 | Up | |
| Carnosine.2 | 2.671–2.662 | 2.03 × 10−15 | Not sig. | Up | |
| 2-Aminoadipate | 2.26–2.247 | 2.10 × 10−15 | Not sig. | Up | |
| Ribose | 4.134–4.106 | 3.55 × 10−14 | Not sig. | Up | |
| Allantoin | 5.401–5.381 | 3.92 × 10−14 | Not sig. | Down | |
| Taurine.1 | 3.448–3.437 | 5.86 × 10−14 | Not sig. | Up | |
| Taurine.2 | 3.426–3.418 | 6.32 × 10−14 | Not sig. | Up | |
| Citramalic acid | 2.75–2.733 | 1.32 × 10−13 | Not sig. | Up | |
| 2-Methylbutyroylcarnitine.2 | 0.8768–0.866 | 1.82 × 10−12 | Not Sig. | Down | |
| 3-Phenyllactate | 7.333–7.316 | 3.02 × 10−12 | 4.45 × 10−2 | Down | |
| 3-indoxylsulfate | 7.513–7.495 | 2.10 × 10−10 | Not sig. | Up | |
| Cysteine-S-sulfate | 3.524–3.511 | 1.01 × 10−09 | Not sig. | Down | |
| 3,4,5-Trimethoxycinnamic acid, Kynurenine | 6.815–6.776 | 1.39 × 10−09 | Not sig. | Down |